Differential Expression of TRAIL and TRAIL Receptors in Allergic Asthmatics Following Segmental Antigen Challenge: Evidence for a Role of TRAIL in Eosinophil Survival1
暂无分享,去创建一个
A. Musani | S. Peters | N. Robertson | G. Litwack | J. Zangrilli | R. Pascual | A. Hastie | A. Steplewski | R. Lindemeyer | Maria A. Planeta | M. Smith | Nathalie Innocent
[1] S. Wenzel,et al. Interleukin-15 inhibits spontaneous apoptosis in human eosinophils via autocrine production of granulocyte macrophage-colony stimulating factor and nuclear factor-kappaB activation. , 2002, American journal of respiratory cell and molecular biology.
[2] N. Kaminski,et al. Interleukin-13 induces dramatically different transcriptional programs in three human airway cell types. , 2001, American journal of respiratory cell and molecular biology.
[3] S. Phipps,et al. Microarray analysis of eosinophils reveals a number of candidate survival and apoptosis genes. , 2001, American journal of respiratory cell and molecular biology.
[4] Xuetao Cao,et al. The Involvement of TNF-α-Related Apoptosis-Inducing Ligand in the Enhanced Cytotoxicity of IFN-β-Stimulated Human Dendritic Cells to Tumor Cells1 , 2001, The Journal of Immunology.
[5] M. Smyth,et al. Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis , 2001, The Journal of experimental medicine.
[6] J. Renauld,et al. Interleukin 9 promotes influx and local maturation of eosinophils. , 2001, Blood.
[7] A. Musani,et al. Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. , 2000, The Journal of allergy and clinical immunology.
[8] T. Di Pucchio,et al. Type I Interferon as a Powerful Adjuvant for Monocyte-Derived Dendritic Cell Development and Activity in Vitro and in Hu-Pbl-Scid Mice , 2000, The Journal of experimental medicine.
[9] C. Maliszewski,et al. Monocyte-mediated Tumoricidal Activity via the Tumor Necrosis Factor–related Cytokine, TRAIL , 1999, The Journal of experimental medicine.
[10] I. Jeremias,et al. TRAIL induces apoptosis and activation of NFkB. , 1999 .
[11] John C. Lee,et al. Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL* , 1998, The Journal of Biological Chemistry.
[12] C. Smith,et al. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. , 1997, Immunity.
[13] J. Tschopp,et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. , 1997, Immunity.
[14] S. Srinivasula,et al. Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.
[15] R. Dubose,et al. Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family , 1997, The Journal of experimental medicine.
[16] Henning Walczak,et al. TRAIL‐R2: a novel apoptosis‐mediating receptor for TRAIL , 1997, The EMBO journal.
[17] R. Gentz,et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. , 1997, Science.
[18] W I Wood,et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.
[19] C. Riccardi,et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] Arul M. Chinnaiyan,et al. The Receptor for the Cytotoxic Ligand TRAIL , 1997, Science.
[21] E. Goillot,et al. Mitogen-activated protein kinase-mediated Fas apoptotic signaling pathway. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[22] S. Peters,et al. Kinetics of the development and recovery of the lung from IgE-mediated inflammation: dissociation of pulmonary eosinophilia, lung injury, and eosinophil-active cytokines. , 1997, American journal of respiratory and critical care medicine.
[23] Vijay R Baichwal,et al. Apoptosis: Activate NF-κB or die? , 1997, Current Biology.
[24] C. Kuo,et al. Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases , 1997, Molecular and cellular biology.
[25] J. Tschopp,et al. TRAMP, a novel apoptosis-mediating receptor with sequence homology to tumor necrosis factor receptor 1 and Fas(Apo-1/CD95). , 1997, Immunity.
[26] M. Arima,et al. Eosinophil peroxidase stimulates the release of granulocyte-macrophage colony-stimulating factor from bronchial epithelial cells. , 1996, The Journal of allergy and clinical immunology.
[27] K. Bauer,et al. Apo-3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB , 1996, Current Biology.
[28] J. Young,et al. CAR1, a TNFR–Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis–Sarcoma Viruses and Mediates Apoptosis , 1996, Cell.
[29] S. Marsters,et al. Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family* , 1996, The Journal of Biological Chemistry.
[30] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[31] D. Goeddel,et al. The TNF receptor 1-associated protein TRADD signals cell death and NF-κB activation , 1995, Cell.
[32] J. Bousquet,et al. Eosinophil inflammation in asthma. , 1994, American journal of respiratory and critical care medicine.
[33] Terry Farrah,et al. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.
[34] W. Busse,et al. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. , 1993, The American review of respiratory disease.
[35] T. Fukuda,et al. Airway hyperresponsiveness, increased intracellular spaces of bronchial epithelium, and increased infiltration of eosinophils and lymphocytes in bronchial mucosa in asthma. , 1992, The American review of respiratory disease.
[36] J. Bousquet,et al. Immunohistochemical characterization of the cellular infiltration in asthmatic bronchi. , 1992, The American review of respiratory disease.
[37] J. Bousquet,et al. Eosinophilic inflammation in asthma. , 1990, The New England journal of medicine.
[38] W. Owen,et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. , 1989, Journal of immunology.
[39] W. Owen,et al. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. , 1988, The Journal of clinical investigation.
[40] J. Gamble,et al. Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. , 1986, The Journal of clinical investigation.
[41] H. Sluiter,et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.
[42] M. Dunnill. THE PATHOLOGY OF ASTHMA, WITH SPECIAL REFERENCE TO CHANGES IN THE BRONCHIAL MUCOSA , 1960, Journal of clinical pathology.